ylliX - Online Advertising Network
Company Ticker News

What Analysts Have To Say On Acadia’s Narrower Nuplazid Label Expansion Bid

What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

RBC Capital raised the price target on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) to $34 from $32 and kept an Outperform rating on the shares.  Analyst Gregory Renza cites the Company’s confirmed intentions to resubmit the sNDA filing of pimavanserin in Alzheimer’s Disease Psychosis, with a “narrower though still robust opportunity” as the largest subtype of DRP.

...read full article on Benzinga

ylliX - Online Advertising Network